Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
Company profile
Ticker
SYRS
Exchange
Website
CEO
Nancy Simonian
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LS22, Inc.
SEC CIK
Corporate docs
Subsidiaries
Syros Securities Corporation • Syros Pharmaceuticals (Ireland) Limited • Tyme Technologies, Inc. • Tyme, Inc. ...
SYRS stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
2 Jun 23
8-K
Regulation FD Disclosure
25 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
424B5
Prospectus supplement for primary offering
1 May 23
EFFECT
Notice of effectiveness
1 May 23
CORRESP
Correspondence with SEC
26 Apr 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
UPLOAD
Letter from SEC
7 Apr 23
Transcripts
SYRS
Earnings call transcript
2023 Q1
10 May 23
SYRS
Earnings call transcript
2022 Q4
2 Mar 23
SYRS
Earnings call transcript
2022 Q3
14 Nov 22
SYRS
Earnings call transcript
2022 Q2
9 Aug 22
SYRS
Earnings call transcript
2022 Q1
16 May 22
SYRS
Earnings call transcript
2021 Q4
15 Mar 22
SYRS
Earnings call transcript
2021 Q3
5 Nov 21
SYRS
Earnings call transcript
2021 Q2
8 Aug 21
SYRS
Earnings call transcript
2021 Q1
9 May 21
SYRS
Earnings call transcript
2020 Q4
4 Mar 21
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 107.85 mm | 107.85 mm | 107.85 mm | 107.85 mm | 107.85 mm | 107.85 mm |
| Cash burn (monthly) | 20.90 mm | (no burn) | 11.07 mm | 11.87 mm | 12.30 mm | 10.83 mm |
| Cash used (since last report) | 45.55 mm | n/a | 24.13 mm | 25.87 mm | 26.81 mm | 23.60 mm |
| Cash remaining | 62.30 mm | n/a | 83.72 mm | 81.98 mm | 81.05 mm | 84.25 mm |
| Runway (months of cash) | 3.0 | n/a | 7.6 | 6.9 | 6.6 | 7.8 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 56 |
| Opened positions | 13 |
| Closed positions | 13 |
| Increased positions | 12 |
| Reduced positions | 16 |
| 13F shares | Current |
|---|---|
| Total value | 20.58 bn |
| Total shares | 14.68 mm |
| Total puts | 0.00 |
| Total calls | 103.20 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Bain Capital Life Sciences Investors | 2.12 mm | $7.63 mm |
| Bain Capital Life Sciences Fund II | 2.12 mm | $0.00 |
| Artal | 1.46 mm | $5.26 mm |
| Artal International S.C.A. | 1.46 mm | $0.00 |
| Ally Bridge MedAlpha Master Fund | 1.44 mm | $0.00 |
| Flagship Pioneering | 993.85 k | $3.57 bn |
| Avidity Partners Management | 900.00 k | $3.23 bn |
| Ally Bridge | 868.40 k | $3.12 bn |
| Adage Capital Partners GP, L.L.C. | 721.91 k | $2.59 bn |
| Vanguard | 472.73 k | $1.70 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Jun 23 | Akkaraju Srinivas | RSU Common Stock | Grant | Acquire A | No | No | 0 | 4,000 | 0.00 | 4,000 |
| 1 Jun 23 | Akkaraju Srinivas | Stock Option Common Stock | Grant | Acquire A | No | No | 3.7 | 6,000 | 22.20 k | 6,000 |
| 1 Jun 23 | Dunsire Deborah | RSU Common Stock | Grant | Acquire A | No | No | 0 | 4,000 | 0.00 | 4,000 |
| 1 Jun 23 | Dunsire Deborah | Stock Option Common Stock | Grant | Acquire A | No | No | 3.7 | 6,000 | 22.20 k | 6,000 |
| 1 Jun 23 | Alles Mark J | RSU Common Stock | Grant | Acquire A | No | No | 0 | 4,000 | 0.00 | 4,000 |
| 1 Jun 23 | Alles Mark J | Stock Option Common Stock | Grant | Acquire A | No | No | 3.7 | 6,000 | 22.20 k | 6,000 |
| 1 Jun 23 | Sue Gail Eckhardt | Common Stock | Grant | Acquire A | No | No | 0 | 4,000 | 0.00 | 12,000 |
| 1 Jun 23 | Sue Gail Eckhardt | Stock Option Common Stock | Grant | Acquire A | No | No | 3.7 | 6,000 | 22.20 k | 6,000 |
| 1 Jun 23 | Oh Andrew M. | Common Stock | Grant | Acquire A | No | No | 0 | 4,000 | 0.00 | 12,000 |
| 1 Jun 23 | Oh Andrew M. | Stock Option Common Stock | Grant | Acquire A | No | No | 3.7 | 6,000 | 22.20 k | 6,000 |
News
HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
11 May 23
JMP Securities Maintains Market Outperform on Syros Pharmaceuticals, Lowers Price Target to $15
11 May 23
Earnings Scheduled For May 10, 2023
10 May 23
Syros Pharmaceuticals: Q1 Earnings Insights
10 May 23
Syros Pharmaceuticals Q1 EPS $(0.85) Beats $(1.09) Estimate, Sales $2.95M Miss $3.26M Estimate
10 May 23
Press releases
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Jun 23
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
25 May 23
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
10 May 23
Syros to Present at JMP Securities 2023 Life Sciences Conference
9 May 23
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
3 May 23